Veraxa Biotech is trading at $1.02, down 10.53%, with no confirmed company-specific catalyst for the November 2, 2026 decline.
- The company’s release page lists October 13, 2026, as its latest release.
- Major indices were higher, so the broader market rebound does not explain the move.
- Earlier research updates do not establish a direct connection to the decline.